VivoSeq
Cardiovascular

Thrombosis

3

Pipeline Programs↗

12

Active Trials↗

5

Companies Involved↗

Thrombosis is an early-stage landscape with 3 programs across 5 companies. The most active players are Bristol-Myers Squibb, Regeneron, Novartis. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

19/100

Mech. Concentration

100/100

Completion Rate

89/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3Regeneron logo

Regeneron

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalC

Canyon Pharmaceuticals, Inc.

0 programs

PreclinicalD

Dr. Kerstin de Wit

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 33

Rivaroxaban

Wim Janssens

Apixaban

Bristol-Myers Squibb

Fondaparinux Injectable Product

Queen Mary University of London

Approved
No programs

Analysis

Trial Status

35

clinical trials

Completed17 · 49%
Recruiting8 · 23%
Unknown status4 · 11%
Not yet recruiting3 · 9%
Terminated2 · 6%
Active, not recruiting1 · 3%

Clinical Trials

Trial Activity

35 trials

Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
Recruiting·—·Phase 3·NCT07140211·9,200 enrolled
Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
Recruiting·CClinical Urology and Epidemiology Working Group·Phase 4·NCT06523959·5,436 enrolled
A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease
Recruiting·Regeneron logoRegeneron·Phase 4·NCT07142343·5 enrolled
Positron Emission Tomography (PET) Imaging of Thrombosis
Recruiting·MMassachusetts General Hospital·Phase 1·NCT03830320·165 enrolled
The Gynecological Cancer Associated Thrombosis (GynCAT) Study
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT06284343·1,800 enrolled
RevCore for In Stent Thrombosis (REVIT)
Recruiting·IInari Medical·N/A·NCT06394739·100 enrolled
Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.
Recruiting·QQueen Mary University of London·Phase 3·NCT06370273·10,044 enrolled
Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients: a Prospective Multicentre Cohort Study
Recruiting·MMedical University of Vienna·N/A·NCT06357403·1,300 enrolled
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT (DEXTERITY-SCI)
Active, not recruiting·MMercator MedSystems, Inc.·Phase 2·NCT04858776·60 enrolled
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
Not yet recruiting·UUniversity Hospital, Geneva·Phase 3·NCT04981327·1,300 enrolled
Delivery and Implementation of a Randomised Crossover Trial on Thrombosis
Not yet recruiting·QQueen Mary University of London·N/A·NCT06937372·21,194 enrolled
Evaluating Superficial Vein Thrombosis in the Emergency Department.
Not yet recruiting·DDr. Kerstin de Wit·N/A·NCT07671300·400 enrolled
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
Completed·JJeffrey Zwicker, MD·Phase 2/3·NCT02195232·64 enrolled
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03692065·1,766 enrolled
Effect of Heparin on Femoral Arterial Sheaths Thrombosis During Diagnostic Coronary Angiography
Completed·PPrince Sultan Cardiac Center, Adult Cardiology Department.·Phase 3·NCT01260519·304 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)